Nostrum Laboratories has recalled all 1 gram Sulcralfate Tablets because it cannot assure the product's identity, strength, quality, or purity. Following a Chapter 11 bankruptcy filing, all operational employees were terminated on September 30, 2024, leading to a vacancy in quality control. This affects tablets manufactured after June 2023. The National Library of Medicine describes Sulcralfate for short-term treatment of duodenal ulcers. Wholesalers and distributors are instructed to destroy the recalled product as Nostrum will not accept returns.
Nostrum Laboratories has recalled all bottles of 1 gram Sulcralfate Tablets, emphasizing it cannot guarantee the product's effectiveness or purity.
After filing for Chapter 11 bankruptcy, Nostrum's operations ceased, resulting in the firing of all employees and a lack of quality control.
Collection
[
|
...
]